Ear, Nose and Throat FDA awards rare pediatric disease designation to OTOF-GT for otoferlin gene-mediated hearing loss Nov. 7, 2022 The FDA has awarded rare pediatric disease...Read More
Ear, Nose and Throat Sensorion receives positive opinion on EU orphan drug designation for OTOF-GT for hearing loss Sep. 13, 2022 The EMA's Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion on Sensorion SA's application seeking orphan drug designation for OTOF-GT, a gene therapy intended for the treatment of otoferlin gene-mediated hearing loss.Read More
